Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality
Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality
复制标题
重症COVID-19患者的细胞因子释放综合征：白细胞介素-6受体拮抗剂托珠单抗可能是降低死亡率的关键
DOI：
10.1016/j.ijantimicag.2020.105954
复制
发表时间：
2020-05-01
影响因子：
10.8
通讯作者：
Wang, Gui-Qiang
中科院分区：
文献类型：
--
作者：
Zhang, Chi;Wu, Zhao;Wang, Gui-Qiang
自2019年12月以来，一种来自中国武汉的名为2019冠状病毒病（COVID-19）的病毒性肺炎席卷全球。虽然病死率不高，但感染人数众多，仍有大量患者死亡。随着越来越多临床资料的整理和发表，大量资料提示重症患者存在轻度或重度的细胞因子风暴，是导致死亡的重要原因。因此，治疗细胞因子风暴已成为抢救重症COVID-19患者的重要组成部分。白细胞介素-6（IL-6）在细胞因子释放综合征中起重要作用。如果能够阻断IL-6的信号转导通路，有望成为治疗重症COVID-19患者的新方法。托珠单抗是一种IL-6受体（IL-6 R）阻断剂，能够有效阻断IL-6信号转导通路，因此很可能成为重症COVID-19患者的有效药物。(C)2020 Elsevier B. V.和国际化疗学会。All rights reserved.
Since December 2019, a viral pneumonia, named coronavirus disease 2019 (COVID-19), from Wuhan, China, has swept the world. Although the case fatality rate is not high, the number of people infected is large and there is still a large number of patients dying. With the collation and publication of more and more clinical data, a large number of data suggest that there are mild or severe cytokine storms in severe patients, which is an important cause of death. Therefore, treatment of the cytokine storm has become an important part of rescuing severe COVID-19 patients. Interleukin-6 (IL-6) plays an important role in cytokine release syndrome. If it is possible to block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe COVID-19 patients. Tocilizumab is an IL-6 receptor (IL-6R) blocker that can effectively block the IL-6 signal transduction pathway and thus is likely to become an effective drug for patients with severe COVID-19. (C) 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.